Emerging immunotherapies for glioblastoma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-45Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research
/in Cervical Cancer, Dendritic Cells, International Publications /von 2016-05-31 / J Gynecol Oncol 2016 Sep;27(5):e51Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-05-31 / Oncoimmunology 2016 Jul;5(7):e1191732Dendritic cell-based cancer immunotherapy for colorectal cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-86Cancer Vaccines in Ovarian Cancer: How Can We Improve?
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2016-05-03 / Biomedicines 2016 May;4(2)Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2016-05-01 / Am. J. Respir. Crit. Care Med. 2016 05;193(9):1023-31Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2016-04-21 / Radiat Oncol 2016 Apr;11:60Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
/in Dendritic Cells, International Publications /von 2016-04-15 / Clin. Cancer Res. 2016 Apr;22(8):1897-906T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-04-11 / Cancer Res. 2016 06;76(12):3496-506IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de